The Cannigma

MAY 1, 2023

According to the DEA, “substances in this schedule have a potential for abuse less than substances in Schedules I or II and abuse may lead to moderate or low physical dependence or high psychological dependence.” And just like that, all of a sudden ketamine had found a new role in modern medicine – an anti-hyperalgesic.

Blood Pressure 80

Blood Pressure Chronic Pain Research and Development Clinical Trials 80

Cannabis Law Report

SEPTEMBER 23, 2019

26 Evidence is most substantial for nausea and vomiting associated with chemotherapy, chronic pain treatment, multiple sclerosis spasticity, and intractable seizures associated with Dravet syndrome and Lennox-Gastaut syndrome. Cannabinoids have been assessed for chronic pain management.

Cannabinoids 40

Cannabinoids Marijuana Research and Development Access 40

The Cannigma

SEPTEMBER 12, 2021

Marijuana (defined in the US as any cannabis plant where THC>0.3%) is a schedule I drug according to the DEA and FDA. But despite lots of marketing efforts that suggest otherwise, D-8 THC is not federally legal and the DEA recently clarified that it is considered a Schedule I substance. THC and PPAR-gamma.

THC 98

THC Research and Development Cannabinoids CBD 98